Regeneron Gets FDA OK for Extended Eylea HD Dosing
By Colin Kellaher
Regeneron Pharmaceuticals has won Food and Drug Administration approval of extended dosing intervals of up to every 20 weeks for its Eylea HD eye drug.
Regeneron on Thursday said the extended dosing covers patients with wet age-related macular degeneration and diabetic macular edema following one year of successful response based on visual and anatomic outcomes.
The Tarrytown, N.Y., biotechnology company said the new dosing regimen allows patients to be treated as infrequently as two to three times a year, further extending the widest range of dosing intervals of any approved injectable anti-vascular endothelial growth factor, or anti-VEGF, therapy.
Eylea HD generated U.S. sales of nearly $1.64 billion last year.
Regeneron, which develops the Eylea franchise with Germany's Bayer, maintains exclusive rights to the products in the U.S., while Bayer has licensed the exclusive marketing rights outside the U.S., where the companies equally split profits from sales.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 02, 2026 12:44 ET (16:44 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
United States